Next-generation ALK-TKI in NSCLC patients
10.3760/cma.j.issn.1008-1372.2018.12.014
- VernacularTitle:下一代ALK-TKI类药物在晚期非小细胞肺癌中的疗效研究
- Author:
Bo YAN
1
;
Yu DONG
;
Bo ZHANG
;
Xueyan ZHANG
;
Tianqing CHU
;
Shuyuan WANG
;
Baohui HAN
Author Information
1. 200030,上海交通大学附属上海市胸科医院肺内科
- Keywords:
Carcinoma,non-small-cell lung/DT;
Sulfones/TU;
Carbazoles/TU;
Organophosphorus compounds/TU;
Lactams,macrocyclic/TU
- From:
Journal of Chinese Physician
2018;20(12):1814-1816
- CountryChina
- Language:Chinese
-
Abstract:
Objective The aim of the study is to investigate the therapeutic efficacy of next-generation anaplastic lynphoma kinase-tyrosine kinase inhibitor (ALK-TKI) in advanced non-small cell lung cancer (NSCLC).Methods The clinical data and outcomes of 22 patients with advanced non-small cell lung cancer who received the next generation of ALK-TKI from 2014 to 2017 in our hospital were retrospectively analyzed.Results 22 patients were included for survival analysis with 15 males and 7 females.The median age was 48 and all of them were adenocarcinoma patients.There were 12,2,7 and 1 patients received ceritinib,alectinib,brigatinib and lorlatinib,respectively.A total of 14 patients could be evaluated,including complete response (CR) in 2 cases,partial response (PR) in 3 cases,stable disease (SD) in 6 cases,progressive disease (PD) in 3 cases.The ORR and DCR were 35.7％ and 78.6％,respectively.The median progression free survival (PFS) of the 22 NSCLC patients was 8.7 months.Progression pattern can be analyzed in 17 patients.Among them,10 patients underwent primary progression (lung),occurring at the leading frequency (accounting for 58.8％) and followed by central nerve system (CNS) progression (accounting for 29.4％).Conclusions Next-generation ALK-TKI provide a reasonable choice for crizotinib-resistant patients.Primary progression (lung) is the leading cause for treatment failure.Multi-disciplinary integration may provide a potential choice for prolonging administration of next-generation ALK-TKI.
